Table 1 Major trials exploring bisphosphonate activity in early breast cancer
From: Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
Trial | Number of patients | Regimen | Duration (years) | Combination therapy | DFS benefit (+/−) | Bone loss benefit (+/−) |
|---|---|---|---|---|---|---|
Z-Fast [45] | 600 | Immediate versus delayed ZA | 5 | Letrozol | NR | + |
ZO-FAST [46] | 1,065 | Immediate versus delayed ZA | 5 | Letrozol | + | + |
NSAPB-34 [44] | 3,323 | Oral clodronate | 3 | Standard therapy according to stage | – (population as a whole) | + |
AZURE [47] | 3,360: premenopausal, 1,504; postmenopausal, 1,531; unknown, 324 | ZA | 5 | Standard therapy according to stage | – (but significant improvements in DFS in postmenopausal women) | + |
Saarto et al. [43] | 299 | Oral clodronate | 3 | Standard therapy according to stage | 29 | NR |
NATAN [48] | 693 | ZA | 5 | Standard therapy according to stage | – (trend for women aged >55) | NR |